Domov › Nemalobunkový karcinóm pľúc › Montana › Billings
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Billings, MT
17 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Billings a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Prebieha náborFáza 3
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Prebieha náborFáza 3
- Billings Clinic Cancer Center, Billings
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Billings Clinic Cancer Center, Billings
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Prebieha náborFáza 3
- Billings Clinic ( Site 3255), Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Prebieha náborFáza 3
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Prebieha náborFáza 3
- St. Vincent Frontier Cancer Center, Billings
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Prebieha náborFáza 3
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Prebieha náborFáza 3
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Prebieha náborFáza 2
- Billings Clinic Cancer Center, Billings
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Prebieha náborFáza 2
- St. Vincent Frontier Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Prebieha náborFáza 1/2
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2/3
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Billings Clinic Cancer Center, Billings
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Prebieha náborObservačná štúdia
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Billings
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Billings
- Rakovina prostaty15 štúdií
- Rakovina pľúc13 štúdií
- Rakovina prsníka10 štúdií
- Rakovina vaječníkov9 štúdií
- Melanóm7 štúdií
- Chronická lymfocytová leukémia7 štúdií
- Akútna myeloidná leukémia7 štúdií
- Rakovina močového mechúra6 štúdií
- Rakovina hrubého čreva6 štúdií
- Kolorektálny karcinóm6 štúdií
- Rektálny karcinóm5 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku4 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.